“Novartis now expects to speak with the FDA about a potential accelerated approval of pelabresib before the end of the year, CEO Vas Narasimhan told investors on a call Tuesday.”
“Novartis CEO says AI has tangibly improved P&L for the first time”
“We have the “replacement power” ahead of patent cliff”
“Novartis CEO Vas Narasimhan tells CNBC the company must keep pursuing acquisitions that could deliver breakthroughs for patients.”